Assessment of Tau Protein Status for Early Detection of Alzheimer's Disease
By LabMedica International staff writers Posted on 03 Jan 2017 |
Image: High molecular weight tau bands (about 80kDa) can be visualized, with greater immunoreactivity, in patients with AD compared with healthy subjects (Photo courtesy of Dr. Ricardo B. Maccioni, University of Chile).
The ratio of normal to aggregated tau protein found in blood platelets has been suggested as a biomarker that could be used for the early detection of Alzheimer's disease.
Investigators at the University of Chile (Santiago, Chile) previously had established the methodology that enables detection of the pathological oligomeric forms of brain tau protein in human blood platelets in patients with Alzheimer's disease (AD) and other neurodegenerative disorders.
The current study cited the use of this methodology to determine whether high molecular weight (HMW) or low molecular weight (LMW) tau protein levels, as well as the ratio HMW/LMW, present in platelets correlated with brain magnetic resonance imaging (MRI) structural changes in normal and cognitively impaired subjects. The investigators examined 53 AD patients and 37 cognitively normal subjects recruited from two memory clinics at the University of Chile. Tau levels in platelets were determined by immunoreactivity and corresponding MRI scans were analyzed.
Results published in the December 20, 2016, issue of the Journal of Alzheimer's Disease revealed that the HMW/LMW tau ratio was statistically different between controls and AD patients, and no associations were noted between HMW or LMW tau and MRI structures. The HMW/LMW tau ratio was associated with reduced volume in the left medial and right anterior cingulate gyri, right cerebellum, right thalamus (pulvinar), left frontal cortex, and right parahippocampal region.
The investigators concluded that this exploratory study showed that the HMW/LMW tau ratio was significantly higher in AD patients than control subjects, and that it was associated with the atrophy of specific regions in the brain. Determination of peripheral markers of AD pathology could help in understanding the pathophysiology of neurodegeneration in AD.
Related Links:
University of Chile
Investigators at the University of Chile (Santiago, Chile) previously had established the methodology that enables detection of the pathological oligomeric forms of brain tau protein in human blood platelets in patients with Alzheimer's disease (AD) and other neurodegenerative disorders.
The current study cited the use of this methodology to determine whether high molecular weight (HMW) or low molecular weight (LMW) tau protein levels, as well as the ratio HMW/LMW, present in platelets correlated with brain magnetic resonance imaging (MRI) structural changes in normal and cognitively impaired subjects. The investigators examined 53 AD patients and 37 cognitively normal subjects recruited from two memory clinics at the University of Chile. Tau levels in platelets were determined by immunoreactivity and corresponding MRI scans were analyzed.
Results published in the December 20, 2016, issue of the Journal of Alzheimer's Disease revealed that the HMW/LMW tau ratio was statistically different between controls and AD patients, and no associations were noted between HMW or LMW tau and MRI structures. The HMW/LMW tau ratio was associated with reduced volume in the left medial and right anterior cingulate gyri, right cerebellum, right thalamus (pulvinar), left frontal cortex, and right parahippocampal region.
The investigators concluded that this exploratory study showed that the HMW/LMW tau ratio was significantly higher in AD patients than control subjects, and that it was associated with the atrophy of specific regions in the brain. Determination of peripheral markers of AD pathology could help in understanding the pathophysiology of neurodegeneration in AD.
Related Links:
University of Chile
Latest Pathology News
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy